You seem to be using an older version of Internet Explorer. This site requires Internet Explorer 8 or higher. Update your browser here today to fully enjoy all the marvels of this site.
A pioneering, decade-long clinical trial was initiated at the Sydney Children's Hospital Randwick and The Children's Hospital at Westmead and was conducted across Australia, New Zealand and the Netherlands.
Children with ALL at the highest risk of relapse were identified early in their treatment plan using a novel test developed by scientists at Children's Cancer Institute Australia (CCIA). This test detects Minimal Residual Disease (MRD) in the bone marrow of children with ALL, who would otherwise appear to be responding well to treatment.
Show Less 